Top Markets
#1 GEKKO GEKKO +53.94%
#2 Helium Helium +50.00%
#3 TENDIES TENDIES +45.07%
#4 Pons Pons +39.32%
#5 ADO Protocol ADO Protocol +39.07%
#6 Prom Prom +31.43%
#7 Collector Crypt Collector Crypt +21.07%
#8 o1.exchange o1.exchange +20.78%
#9 Nillion Nillion +20.10%
#10 龙虾 (Lobster) 龙虾 (Lobster) +18.75%
Coin of the day
GEKKO GEKKO
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Jiangsu Yahong Meditech Co Ltd Jiangsu Yahong Meditech Co Ltd

Jiangsu Yahong Meditech Co Ltd

688176
Rangering i aksjer #9583
Established in 2010 and headquartered in Shanghai, China, Jiangsu Yahong... Established in 2010 and headquartered in Shanghai, China, Jiangsu Yahong Meditech Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutic drugs. Its primary focus lies in medicines targeting genitourinary system cancers, though its pipeline extends to a variety of other diseases, serving both domestic Chinese and international markets. The company's clinical-stage pipeline features several key candidates. Notably, two compounds, APL-1202 (an anti-tumor drug) and APL-1706 (an agent drug), are both undergoing Phase III trials for the treatment of non-muscle invasive bladder cancer. Another promising candidate, APL-1501, an oral MetAP inhibitor, is currently in Phase I testing for addressing urinary system tumors and drug-resistant urinary tract infections. Furthermore, APL-1702, a photodynamic therapy product, is in Phase III for tackling cervical high-grade squamous intraepithelial lesions that arise from HPV infections. Beyond these clinical programs, Jiangsu Yahong Meditech is actively exploring targeted protein degraders in its preclinical phase. This includes ASN-1764, aimed at triple-negative breast cancer; ASN-1780, intended for metastatic castration-resistant prostate cancer; and APL-1901, designed to treat ER-positive breast cancer. The company's developmental efforts also encompass APL-1401, targeting moderately to severely active ulcerative colitis, and ASN-1733, for combating Acinetobacter baumannii infection.
Aksjekurs
$1.72
Sist synkronisert: 2026-08-28
Markedsverdi
$985.07M
Endring (1 dag)
-0.50%
Endring (1 år)
6.01%
Land
CN
Handel Jiangsu Yahong Meditech Co Ltd (688176)

Kategori

Healthcare
Aksjeprishistorikk for Jiangsu Yahong Meditech Co Ltd (688176)
Høyeste sluttskurs: $1.81 den 2026-08-01

Laveste sluttskurs: $2.70 den 2022-01-01
Aksjeprishistorikk for Jiangsu Yahong Meditech Co Ltd fra 2022 til 2026
Årlig aksjeprisytelse
År Ytelse
2026 (TTM) 14.02%
2025 47.19%
2024 -34.35%
2023 -4.03%
2022 0.00%
Aksjepris for lignende selskaper eller konkurrenter
Selskap Aksjepris Endring 1år% Land
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 $171.67 -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 $166.36 31.46%
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 $37.84 25.87%
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 $222.33 27.49%
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $21.19 17.16%
IN